Press Room

Webinar - One - fruitful - long shot: extended release approaches for small and large molecules

Start
Wednesday, November 25, 2020 - 16:00
End
Wednesday, November 25, 2020 - 16:00
Location: online

 

Wednesday, November 25th, 2020
4:00pm GMT   |   11:00 am EDT  |   5:00 pm CEST

 

Registrations to the webinar are subject to approval

 

 

Speakers

Cláudia Moura, PhD - Senior Scientist, R&D Drug Product Development
Teresa Marta, MSc - Associate Analytical Chemist, R&D Analytical Development

 

Drug-delivery systems administered by injection that allows controlled-release are highly desirable due to the reduced frequency of administrations that can range from weeks to months or even years, increasing patient compliance while providing the same therapeutic efficiency.

In this webinar, we will address insights into the formulation and available particle engineering technologies for controlled delivery of small molecules and biopharmaceuticals using Poly(lactic-co-glycolic) Acid (PLGA) as biodegradable polymer. We will also explore standard and advanced material characterization techniques including accelerated in vitro release (IVR) methods which have received considerable attention to expedite time required for batch release. 

This webinar will present Hovione’s approach for controlled release PLGA formulations throughout the manufacturing process and product characterization. You can hear about several manufacturing techniques available at Hovione that are followed by case-studies; the analytical characterization will also be showcased focusing on real time and accelerated IVR.

 

What can you learn from this webinar?

  • Controlled release systems - delivery routes
  • Formulation and manufacturing approaches

 

 

Watch On-Demand Webinar!

(Restricted Access)

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026